XLO
Xilio Development Inc
NASDAQ: XLO · HEALTHCARE · BIOTECHNOLOGY
$7.92
+1.67% today
Updated 2026-04-30
Market cap
$45.80M
P/E ratio
—
P/S ratio
1.05x
EPS (TTM)
$-4.19
Dividend yield
—
52W range
$6 – $17
Volume
0.2M
Xilio Development Inc (XLO) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $6.34M | $43.77M |
| Revenue growth (YoY) | — | — | — | — | — | — | +589.9% |
| Cost of revenue | $240000.00 | $1.06M | $1.50M | $1.85M | $1.90M | $1.64M | $1.54M |
| Gross profit | $-240000.00 | $-1.06M | $-1.50M | $-1.85M | $-1.90M | $6.34M | $42.23M |
| Gross margin | — | — | — | — | — | 100.0% | 96.5% |
| R&D | $14.26M | $43.91M | $51.19M | $59.20M | $52.14M | $41.21M | $56.04M |
| SG&A | $4.77M | $10.65M | $23.86M | $29.95M | $27.00M | $24.78M | $29.71M |
| Operating income | $-19.03M | $-54.56M | $-75.04M | $-89.15M | $-79.13M | $-60.58M | $-41.98M |
| Operating margin | — | — | — | — | — | -954.9% | -95.9% |
| EBITDA | $-17.07M | $-53.55M | $-73.55M | $-87.30M | $-77.23M | $-58.00M | $-40.44M |
| EBITDA margin | — | — | — | — | — | -914.3% | -92.4% |
| EBIT | $-17.31M | $-54.62M | $-75.04M | $-89.15M | $-79.13M | $-59.65M | $-41.98M |
| Interest expense | $0.00 | $600000.00 | $756000.00 | $927000.00 | $127800.00 | $100000.00 | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-17.31M | $-55.22M | $-74.30M | $-87.30M | $-76.40M | $-58.24M | $-35.04M |
| Net income growth (YoY) | — | -219.0% | -34.6% | -17.5% | +12.5% | +23.8% | +39.8% |
| Profit margin | — | — | — | — | — | -918.0% | -80.1% |